A Phase 1 interventional study of Formulation A GS-248 and Formulation B GS-248 in Pharmacokinetic, sponsored by Gesynta Pharma AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-31.
Sponsored by Gesynta Pharma AB · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.
The study is divided in two parts. Part I will evaluate PK, safety and tolerability of a single oral dose of two different formulations of GS-248 in fasting conditions. Part II will evaluate PK, safety and tolerability of one of the two different formulations of GS-248 in fed conditions.
In Part I, a single oral dose of GS-248 in two different solid formulations will be administered to 14 healthy subjects. All subjects will first receive Formulation A and then Formulation B. A wash-out period of at least 4 days will be applied between the IMP administrations. Both doses contain 120 mg GS 248. For Part I, subjects will come to the clinic for single dose administration of Formulation A or Formulation B, respectively, and PK and safety assessments. Safety assessments include AE reporting, physical examination, ECG, vital signs, body temperature, and blood sampling for analysis of safety laboratory parameters.
After evaluation of the PK profiles of Formulation A and B in Part I of the study, one formulation will be selected to be given following intake of a standardised breakfast in Part II of the study. Subjects will return to the clinic for a second dose of the selected formulation, yet now in fed conditions. The assessments during fed conditions will be the same as during fasting conditions except that the subjects will consume a high-fat high-calorie breakfast 30 minutes prior to IMP administration.
Gesynta Pharma AB is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Formulation A given in fasting state.
Drug: Formulation A GS-248
Formulation B given in fasting state.
Drug: Formulation B GS-248
Formulation A or B given in fed condition
Drug: Formulation A GS-248 · Drug: Formulation B GS-248
Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
Cmax
The Maximal Plasma Concentration (Cmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
AUC0-inf
The Area Under the Curve (AUC) for the time interval 0-infinity of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
AUC0-24h
The Area Under the Curve (AUC) for the time interval 0-24h of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 for the time interval 0-24 h was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: From time 0 (time of dosing) to 24 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
Tmax
Time to Cmax (Tmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: From time 0 (time of dosing) to 48 hours after dose (concentration measured at timepoints pre-dose and 0:15, 0:30, 1, 1:30, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours post-dose)
T1/2(z)
Plasma half-life associated with the terminal elimination phase (T1/2(z)) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: T1/2 (z) was assessed for the terminal elimination phase up to 48 hours
Vz/F
The mean volume of distribution (Vz/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: Vz/F was assessed for the terminal elimination phase up to 48 hours.
CL/F
The mean total clearance (CL/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean total clearance (CL/F) was calculated by non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
Time frame: CL/F was assessed for a single dose of GS-248 up to 48 hours.
Number of Treatment Related Adverse Events
The grading of the severity/intensity (grade 1 to grade 5) of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed by the Investigator as "unlikely", "possibly" or "probably" related to the IMP. An AE was considered causally related to the use of the IMP when the causality assessment was "probable" or "possible".
Time frame: AEs (including serious AEs [SAEs]) were collected from the start of IMP application in Part I until the end-of- study visit i.e. Visit 7, day 3, up to 30 days.
Number of Clinically Significant (CS) Changes in Physical Examination
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A short version of physical examination included an assessment of selected body systems at the judgement of the Investigator but at least included cardiovascular, lung and abdomen. The results of the examinations were documented in the eCRF as normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Post-dose physical examination findings judged as abnormal CS were reported as AEs.
Time frame: Physical examination was performed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Number of Clinically Significant (CS) Changes in Vital Signs
Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Vital signs were judged as normal, abnormal NCS or abnormal CS.
Time frame: Vital signs ware assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Number of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG)
Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. HR and PR, QRS, QT and QTcF intervals were recorded. Safety ECGs were reviewed and interpreted on-site by the Investigator. All ECGs were categorised as "normal", "abnormal, not clinically significant", or "abnormal, clinically significant".
Time frame: ECG evaluation was assessed at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
Number of Clinically Significant (CS) Changes in Safety Laboratory Parameters
Blood samples for analysis of clinical chemistry and haematology parameters were collected through venepuncture or an indwelling venous catheter and sent to the certified clinical chemistry laboratory at Uppsala University Hospital and analysed by routine analytical methods. Urine analysis was performed at the research clinic using dip sticks. Safety laboratory parameters were judged as normal, abnormal NCS or abnormal CS.
Time frame: Blood samples were collected at pre-defined timepoints from the Screening Visit until the End-of- Study Visit i.e. Visit 7, day 3, up to 30 days.
The subjects were recruited from CTC's database of healthy volunteers and from advertising in media (including social media). Screening visits were performed at CTC research clinic. Recruitment period started 24MAR2020 (the day after approval received from IEC and CA) and lasted until 06APR2020 (date for last subject screened).
| Milestone | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Started | 14 | 0 | 0 |
| Completed | 14 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Started | 0 | 14 | 0 |
| Completed | 0 | 14 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Started | 0 | 0 | 14 |
| Completed | 0 | 0 | 13 |
| Not completed | 0 | 0 | 1 |
The Maximal Plasma Concentration (Cmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| nmol/L | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| Cmax | 508.6 ± 220.9 | 384.5 ± 219.1 | 289.5 ± 184.4 | 499.5 ± 227.2 |
The Area Under the Curve (AUC) for the time interval 0-infinity of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| h*nmol/L | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| AUC0-inf | 1491 ± 478.1 | 1182 ± 567.4 | 1119 ± 463.9 | 1494 ± 497.4 |
The Area Under the Curve (AUC) for the time interval 0-24h of GS-248 after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean AUC of GS-248 for the time interval 0-24 h was assessed by means of non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| h*nmol/L | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| AUC0-24h | 1420 ± 459.4 | 1104 ± 527.2 | 1014 ± 377.6 | 1419 ± 478.2 |
Time to Cmax (Tmax) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| hours | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| Tmax | 1.500 (1.00 to 3.00) | 1.500 (1.00 to 3.03) | 3.000 (1.00 to 4.03) | 1.500 (1.00 to 3.00) |
Plasma half-life associated with the terminal elimination phase (T1/2(z)) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| hours | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| T1/2(z) | 10.69 ± 2.912 | 16.09 ± 15.26 | 13.36 ± 9.914 | 10.91 ± 2.902 |
The mean volume of distribution (Vz/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| L | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| Vz/F | 2071 ± 1035 | 3884 ± 2940 | 3110 ± 1588 | 2125 ± 1057 |
The mean total clearance (CL/F) after a single dose of Formulation A and B of GS 248 respectively in fasting conditions and after a single dose of Formulation A of GS-248 in fed condition. The mean total clearance (CL/F) was calculated by non-compartmental analysis (NCA). Blood samples for bioanalysis of GS-248 and subsequent PK analysis were collected as venous blood samples.
| L/h | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition | Part II GS-248 Formulation A in Fasting Condition (Partial Set) |
|---|---|---|---|---|
| CL/F | 132.9 ± 50.59 | 191.4 ± 105.0 | 185.2 ± 76.08 | 133.7 ± 52.56 |
The grading of the severity/intensity (grade 1 to grade 5) of AEs followed the common terminology criteria for AEs (CTCAE) v5.0. AEs were assessed by the Investigator as "unlikely", "possibly" or "probably" related to the IMP. An AE was considered causally related to the use of the IMP when the causality assessment was "probable" or "possible".
| events | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Number of Treatment Related Adverse Events | 7 | 3 | 1 |
A complete physical examination included assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities. A short version of physical examination included an assessment of selected body systems at the judgement of the Investigator but at least included cardiovascular, lung and abdomen. The results of the examinations were documented in the eCRF as normal, abnormal not clinically significant (NCS) or abnormal clinically significant (CS). Post-dose physical examination findings judged as abnormal CS were reported as AEs.
| Number of abnormal CS events | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Number of Clinically Significant (CS) Changes in Physical Examination | 0 | 0 | 0 |
Systolic and diastolic blood pressure and pulse were measured in supine position after 10 minutes of rest. Vital signs were judged as normal, abnormal NCS or abnormal CS.
| Number of abnormal CS events | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Number of Clinically Significant (CS) Changes in Vital Signs | 0 | 0 | 0 |
Single 12-lead ECG was recorded in supine position after 10 minutes of rest using an ECG machine. HR and PR, QRS, QT and QTcF intervals were recorded. Safety ECGs were reviewed and interpreted on-site by the Investigator. All ECGs were categorised as "normal", "abnormal, not clinically significant", or "abnormal, clinically significant".
| Number of abnormal CS events | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Number of Clinically Significant (CS) Changes in Resting 12-lead Electrocardiogram (ECG) | 0 | 0 | 0 |
Blood samples for analysis of clinical chemistry and haematology parameters were collected through venepuncture or an indwelling venous catheter and sent to the certified clinical chemistry laboratory at Uppsala University Hospital and analysed by routine analytical methods. Urine analysis was performed at the research clinic using dip sticks. Safety laboratory parameters were judged as normal, abnormal NCS or abnormal CS.
| Number of abnormal CS events | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| Number of Clinically Significant (CS) Changes in Safety Laboratory Parameters | 0 | 1 | 1 |
Collected over Adverse events, AEs (including SAEs), were collected from the start of IMP administration until the End-of-study Visit i.e. Visit 7, day 3, up to 30 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part I GS-248 Formulation A | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Part I GS-248 Formulation B | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| Part II GS-248 Formulation A in Fed Condition | 0/13 (0%) | 0/13 (0%) | 2/13 (15.4%) |
| Event | Part I GS-248 Formulation A | Part I GS-248 Formulation B | Part II GS-248 Formulation A in Fed Condition |
|---|---|---|---|
| HeadacheNervous system disorders | 6/14 | 3/14 | 1/13 |
| Haemoglobin decreasedInvestigations | 0/14 | 0/14 | 1/13 |
| AnaemiaBlood and lymphatic system disorders | 0/14 | 1/14 | 0/13 |
| FlatulenceGastrointestinal disorders | 0/14 | 1/14 | 0/13 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 0/14 | 1/14 | 0/13 |
| Age, Continuous(years) | Overall Trial |
|---|---|
| Mean | 44.3 ± 17.1 |
| Sex: Female, Male(Participants) | Overall Trial |
|---|---|
| Female | 10 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Overall Trial |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Trial |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall Trial |
|---|---|
| Sweden | 14 |
| Height(cm) | Overall Trial |
|---|---|
| Mean | 171.6 ± 10.8 |
| Weight(kg) | Overall Trial |
|---|---|
| Mean | 74.5 ± 17.14 |
| BMI(kg/m^2) | Overall Trial |
|---|---|
| Mean | 25.1 ± 3.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in May 2020, 1 month.
Results were first posted in Aug 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gesynta Pharma AB